Scarica l'app Stockscreener
35.65
1.05%
0.37
Dopo l'orario di chiusura:
35.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Celldex Therapeutics Inc (CLDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Celldex: 'Strong Buy' Barzolvolimab Carries To Q4 2026 CSU Data Readouts (NASDAQ:CLDX) - Seeking Alpha
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2 - TradingView
CLDX|Celldex Therapeutics Inc|Price:35.280|Chg%:-0.140 - TradingKey
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year? - Yahoo Finance
Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run - Sahm
A Quick Look at Today's Ratings for Celldex Therapeutics(CLDX.US), With a Forecast Between $40 to $70 - Moomoo
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Bristol-Myers Squibb (BMY) and Peptidream (OtherPPTDF) - The Globe and Mail
CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78 - webull.com
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial DiscontinuationSlideshow (NASDAQ:CLDX) 2026-07-22 - Seeking Alpha
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study - BioPharma Dive
Drum KIT: Celldex CSU rhythm still on post-barzo PN phase II - BioWorld News
Stifel Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $68 - Moomoo
Celldex cuts price target after halting Phase 2 trial for key drug due to efficacy failure. - Pluang
Celldex Stands By Barzolvolimab in CSU After Prurigo Nodularis Miss - insights.citeline.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower - Benzinga
Canaccord cuts Celldex stock price target after trial miss By Investing.com - Investing.com Canada
Celldex Treatment Fails To Relieve Chronic Itch, Abandons Prurigo Nodularis Study - Benzinga
Celldex scraps antibody in itchy skin nodules after Phase 2 flop - Endpoints News
Celldex drops Phase II study of barzolvolimab in prurigo nodularis - The Pharma Letter
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss - Yahoo Finance
Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating - marketscreener.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - Sahm
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff? - Yahoo Finance
Celldex discontinues prurigo nodularis trial after phase 2 miss - Investing.com
Celldex to End Phase 2 Study for Skin-Disease Treatment - Moomoo
Celldex stock falls after phase 2 trial misses key endpoints By Investing.com - Investing.com Canada
Celldex discontinues prurigo nodularis trial after phase 2 miss By Investing.com - Investing.com Canada
Celldex stock falls after phase 2 trial misses key endpoints - Investing.com
Celldex Drug Depleted Mast Cells but Did Not Ease PN Itch - Stock Titan
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Biotech Gem with 64% Potential Upside - DirectorsTalk Interviews
Guggenheim raises Celldex stock price target on trial outlook By Investing.com - Investing.com Canada
MSN Money - msn.com
Celldex Therapeutics, Inc. Announces Retirement of Sam Martin from Senior Vice President, Effective on or About March 31, 2027 - marketscreener.com
Celldex Therapeutics, Inc. Announces Retirement of Sam Martin as Chief Financial Officer, Effective on or About March 31, 2027 - marketscreener.com
Celldex Therapeutics CFO Plans to Retire in 2027 - marketscreener.com
Celldex CFO Sam Martin to retire in March 2027 By Investing.com - Investing.com Canada
Celldex CFO Sam Martin to Retire; Company Begins Search for Successor - TradingView
Celldex CFO Sam Martin to retire in March 2027 - Investing.com
Celldex Therapeutics (NASDAQ: CLDX) CFO to retire around March 2027 - Stock Titan
Celldex Starts CFO Search as Martin Plans 2027 Retirement - Stock Titan
Press Release: Celldex Announces Planned Transition of Chief Financial Officer - Moomoo
Celldex Therapeutics (CLDX) Gets Fresh Index Attention As Valuation Debate Heats Up - simplywall.st
Celldex Therapeutics stock hits 52-week high at 39.16 USD By Investing.com - Investing.com Nigeria
Celldex Therapeutics stock hits 52-week high at 39.16 USD - Investing.com
Price to sales forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Price to book forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Celldex Therapeutics (CLDX) Is Up 8.8% After Broad Russell Growth Index Additions Has The Bull Case Changed? - Sahm
Price to earnings forward of Celldex Therapeutics, Inc. – NASDAQ:CLDX - TradingView
Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus - Sahm
CLDX Stock Price, Quote & Chart - ChartMill
CLDX SEC FilingsCelldex Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Wells Fargo Maintains Celldex Therapeutics(CLDX.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Celldex Therapeutics (CLDX) Holds Near Support After Minor DeclineGrowth Stock Picks - dars.gov.et
CLDX Q1 2026 Earnings: EPS Misses Estimates as Biotech Focuses on Pipeline ProgressEarnings Season Review - dars.gov.et
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval? - Yahoo Finance
Form 4 Celldex Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
[Form 4] Celldex Therapeutics, Inc. Insider Trading Activity - Stock Titan
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):